Healthcare
•3755 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3755)
| Company | Market Cap | Price |
|---|---|---|
|
OBIO
Orchestra BioMed Holdings, Inc.
AVIM therapy is an implantable cardiac stimulation-based treatment for hypertension, aligning with Cardiology Devices.
|
$258.98M |
$4.82
-0.41%
|
|
INZY
Inozyme Pharma, Inc.
Inozyme focuses on ENPP1 Deficiency, a rare disease, with INZ-701 as a lead therapy, making it a dedicated rare-disease biopharma company.
|
$256.96M |
$4.00
|
|
NGNE
Neurogene Inc.
NGNE directly develops gene therapy candidates (NGN-401) and uses a gene therapy platform, matching Biotech - Gene Therapy.
|
$255.75M |
$18.02
-3.53%
|
|
PROF
Profound Medical Corp.
Profound's flagship TULSA-PRO is a surgical device used for MR-guided prostate tissue ablation.
|
$253.65M |
$8.40
-0.94%
|
|
BNR
Burning Rock Biotech Limited
Burning Rock's brPROPHET MRD and MCED products are ctDNA-based diagnostics delivered as a liquid biopsy test.
|
$250.90M |
$22.85
-2.35%
|
|
MPAA
Motorcar Parts of America, Inc.
MPAA markets and sells diagnostic equipment, such as the JBT-1 Bench Top tester.
|
$249.06M |
$13.04
+1.36%
|
|
QSI
Quantum-Si incorporated
The company manufactures diagnostic-grade hardware instruments (Platinum/Proteus) used for proteomics analysis.
|
$247.04M |
$1.23
-2.00%
|
|
ALDX
Aldeyra Therapeutics, Inc.
Lead reproxalap for dry eye disease is an ophthalmic drug, representing a direct product in ophthalmology.
|
$246.17M |
$4.07
-2.75%
|
|
SNFCA
Security National Financial Corporation
Death care services (cemetery and mortuary) are a direct service offering aligned with healthcare services and facilities.
|
$243.98M |
$9.41
+0.21%
|
|
MGRM
Monogram Orthopaedics, Inc.
Direct product category: Monogram's system is a surgical device used in operating rooms for orthopedic procedures.
|
$243.79M |
$6.00
|
|
ASMB
Assembly Biosciences, Inc.
Assembly Biosciences develops small-molecule antiviral therapeutics, including HSV helicase-primase inhibitors, HDV entry inhibitors, HBV capsid assembly modulators, and NNPI programs.
|
$243.52M |
$31.60
+0.13%
|
|
GNFT
Genfit S.A.
GENFIT's ELAFIBRONOR in Primary Biliary Cholangitis (PBC) represents a core liver-disease therapeutic offering.
|
$242.48M |
$4.90
+1.03%
|
|
SLQT
SelectQuote, Inc.
Healthcare Services & Facilities encompasses SelectRx and other healthcare services provided via the platform.
|
$241.94M |
$1.40
-1.06%
|
|
ELMD
Electromed, Inc.
Electromed manufactures the SmartVest Clearway airway clearance medical device, fitting the Medical Devices & Biometrics investable theme.
|
$240.46M |
$28.79
-0.79%
|
|
CIA
Citizens, Inc.
Accident & health (A&H) / health insurance offerings are mentioned as part of the product mix.
|
$239.67M |
$4.72
-1.15%
|
|
RZLT
Rezolute, Inc.
Ersodetug is a human monoclonal antibody designed to treat HI by modulating insulin signaling, representing a monoclonal antibody therapeutic product.
|
$238.83M |
$2.63
+11.18%
|
|
OABI
OmniAb, Inc.
OmniAb's core offering is the Antibody Discovery Platform enabling rapid generation of human antibodies through engineered transgenic animals and associated discovery tools.
|
$234.36M |
$1.92
+1.32%
|
|
SMTI
Sanara MedTech Inc.
bone fusion/orthopedic implants (BiFORM, ALLOCYTE Plus) and associated bone void filler (OsStic) place the company in Orthopedic Devices.
|
$230.66M |
$25.48
-1.66%
|
|
SLRN
Acelyrin, Inc.
Lonigutamab is a monoclonal antibody therapeutic (IGF-1R) being developed as a treatment for TED, aligning with Monoclonal Antibody Therapeutics.
|
$228.61M |
$2.27
|
|
STXS
Stereotaxis, Inc.
Catheter-based cardiology devices (ablation/catheters) are a core direct product, fitting Cardiology Devices.
|
$227.54M |
$2.54
-1.74%
|
|
STTK
Shattuck Labs, Inc.
SL-325 is a monoclonal antibody targeting DR3, making Monoclonal Antibody Therapeutics a direct product category.
|
$227.54M |
$4.74
+2.16%
|
|
QNCX
Quince Therapeutics, Inc.
Quince's AIDE platform is a drug-delivery platform encapsulating drugs in autologous red blood cells.
|
$226.67M |
$4.28
-2.73%
|
|
TKNO
Alpha Teknova, Inc.
Teknova is the exclusive US/Canada manufacturer and distributor of the PluriFreeze PF10 cryopreservation system, a medical device.
|
$224.23M |
$4.13
+2.99%
|
|
VYGR
Voyager Therapeutics, Inc.
Voyager’s core offerings are gene therapies and gene-delivery platforms, including APOE and tau-targeted approaches.
|
$222.98M |
$4.03
-0.74%
|
|
AVTX
Avalo Therapeutics, Inc.
AVTX-9.00 is an anti-IL-1β monoclonal antibody, directly fitting Monoclonal Antibody Therapeutics.
|
$222.93M |
$16.99
-0.70%
|
|
TARA
Protara Therapeutics, Inc.
TARA-2.00 is a cell therapy platform, representing the company’s lead product modality.
|
$221.85M |
$5.79
+3.30%
|
|
OMI
Owens & Minor, Inc.
OMI sells and distributes medical devices and biometric equipment for home healthcare and clinical use.
|
$216.57M |
$2.80
|
|
NVCT
Nuvectis Pharma, Inc.
Nuvectis' lead asset NXP900 is a cancer-targeting therapy (SRC/YES1 kinase inhibitor), placing the company in Biotech - Oncology.
|
$215.36M |
$8.36
-5.54%
|
|
RNAC
Cartesian Therapeutics, Inc.
Lead platform is an autologous cell therapy using mRNA CAR-T, a direct cell-therapy product line.
|
$213.22M |
$7.89
-2.83%
|
|
HRTX
Heron Therapeutics, Inc.
Biochronomer drug-delivery technology is a platform enabling extended-release formulations across Heron's products.
|
$213.08M |
$1.47
+15.35%
|
Showing page 21 of 38 (3755 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
